menu
    • menu

    Company profile for AGC Pharma Chemicals Europe

    NEW Drugs in Dev: 1
    Mix Gif-PSE
    News
    AGC Pharma Chemicals to Attend CDMO Live Rotterdam

    29 Apr 2026

    // PRESS RELEASE

    AGC Pharma to Attend Connection Day 2026 in Barcelona

    21 Apr 2026

    // PRESS RELEASE

    AGC Pharma Chemicals will participate in CPHI Japan 2026

    08 Apr 2026

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    #1

    Contact Supplier

    Website

    CDMO Live Europe 2026

    Booth #S46

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    https://www.youtube.com/embed/z-rLIzDHFD8?si=Etj_GYLRLvJuRNuJ

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    Key Products KEY PRODUCTS

    SERVICES

    Key Products KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Related CompaniesRelated Companies

    About

    AGC Pharma Chemicals Europe is a leading CDMO partner for Small Molecule APIs, HPAPIs, and intermediates. It provides comprehensive, agile, and innovative solutions throughout the entire lifecycle of API and HPAPI development and manufacturing, from clinical phase I to commercialization. Committed to top pharma quality standards, AGC Pharma Chemicals Europe aims to be the first-choice, most trusted CDMO, improving lives through high-quality products and services. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AGC Pharma Chemicals EuropeSpain_new Flag
    Country
    Country
    Spain
    Address
    Address
    Camí de la Pomereda, 13 08380 Malgrat de Mar (Barcelona)
    Telephone
    Telephone
    -
    Client Email
    Email
    apce.malsm.contact@agc.com
    Client Website
    Website
    https://www.agcpharmachemicals.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/agc-pharma-chemicals-europe-s-l-u/
    youtube
    YouTube
    http://www.youtube.com/@AGCPharmaChemicals
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CDMO Live Europe 2026

    Booth #S46

    envelop Contact Supplier

    CDMO Live Europe 2026

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/agc-pharma-chemicals-europe-party-content-24823.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    CDMO Activity Tracker: Veranova, ChemExpress invest in ADC facilities; Cohance to set up oligonucleotide facility in India

    CDMO Activity Tracker: Veranova, ChemExpress invest in ADC facilities; Cohance to set up oligonucleotide facility in India

    The contract development and manufacturing organization (CDMO) sector has emerged as a key partner in new drug development. This was evident from the strategic investments, partnerships, and expansions witnessed in the third quarter (Q3) of 2025. Several CDMOs, such as Cohance Lifesciences, Fermion Oy, Axplora, AGC Pharma Chemicals invested in new projects. Others, including Veranova, Aenova, and Biosynth, expanded capacities, while Ofichem strengthened its footprint with the acquisition of Avivia BV. CDMOs like Fareva, Evonik, and Samsung Biologics forged strategic partnerships for growth. During Q3, the sector continued to adopt artificial intelligence (AI). This prompted the US Food and Drug Administration (FDA) to issue guidance that recognizes the increasing use of AI and data analytics in drug development.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Cohance, Veranova invest in bioconjugation suites in US; ChemExpress inks ADC deal Earlier this year, Indian drugmaker Suven Pharmaceuticals Limited merged with  leading CDMO Cohance Lifesciences Limited. The merged entity — Cohance Lifesciences — has invested US$ 10 million in a current Good Manufacturing Practice (cGMP) bioconjugation suite at its subsidiary NJ Bio in Princeton, New Jersey.  NJ Bio is executing a major program for an existing innovator client with multiple antibody-drug conjugate (ADC) candidates. Cohance also announced an INR 230 million (approximately US$ 2.58 million) investment in a cGMP oligonucleotide facility at its Hyderabad (India) site. Veranova’s Devens (Massachusetts) site successfully passed a routine FDA cGMP surveillance inspection with a “No Action Indicated” (NAI) classification. Earlier, the company had initiated a US$ 50 million investment to expand its ADC and bioconjugate capabilities at its Devens site. This includes a 9,000-square-foot facility expansion with a new process development lab, two additional cGMP suites, and state-of-the-art bioconjugation development and manufacturing capabilities. These initiatives strengthen the site’s highly potent API (HPAPI) and ADC development and manufacturing capabilities. Biosynth has expanded its Berlin facility with a new GMP bioconjugation suite. The expansion supports the company’s manufacturing capabilities in conjugate vaccines, conjugate drugs, activated polyethylene glycol (PEGs), and polymer-based drug delivery excipients. ChemExpress, Mabwell Bioscience, and Insilico Medicine have entered into a strategic partnership to jointly develop a large ADC compound library and advance next-generation ADC candidates. The collaboration combines Mabwell’s antibody and ADC technology, Insilico’s AI-powered drug design platform, and ChemExpress’s expertise in linker-payload chemistry. Together, they aim to build a complete, AI-driven ADC development model that accelerates discovery, optimization, and commercialization. This partnership is expected to enhance R&D efficiency and deliver safer, more effective cancer treatments.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Fermion, Axplora, Aenova increase API manufacturing capacities; ICE Pharma expands India facility Finnish CDMO Fermion Oy has launched a renovation project at its Hanko (Finland) production site to modernize its API manufacturing capabilities. This expansion is part of Fermion's broader strategy to increase production, enhance flexibility in the manufacturing of both existing and future pharmaceutical products, and enable potential contract manufacturing opportunities. German CDMO Axplora has announced a €6.5 million (approximately US$ 7.5 million) investment to expand its API manufacturing capacity at its Vizag site in India. This expansion aims to strengthen both production capabilities and supply chain resilience. India-based Aarti Pharmalabs has inaugurated the first phase of its greenfield manufacturing facility in Gujarat (India). This expansion aims to bolster Aarti's CDMO and contract manufacturing organization (CMO) services, targeting a revenue goal of INR 10 billion (approximately US$ 112 million). Snapdragon Chemistry, which was acquired by Cambrex in 2023, has expanded its Massachusetts facility to better support peptide drug development and manufacturing. With this upgrade, the company can now handle peptide projects from early development through full-scale manufacturing. Italy-headquartered ICE Pharma has expanded its Raichem facility in India. The new facility will enhance the production of ursodeoxycholic acid (UDCA), an API it derives from chicken bile. This expansion increases the site’s raw UDCA output by 120 metric tons annually. Spain-headquartered AGC Pharma Chemicals inaugurated a new advanced manufacturing plant in Barcelona, with an investment of €110 million (approximately US$ 128.3 million). The plant spans 7,500 square meters and integrates cutting-edge technologies to support the entire drug development lifecycle — from R&D to commercial manufacturing. This represents a 30 percent increase in the company’s production capacity and introduces a segment dedicated to HPAPIs. Germany-headquartered Aenova has launched a new hot melt extrusion platform at its Regensburg (Germany) site. This new equipment enables the production of advanced drug formulations, while handling all testing and quality checks in-house. The move strengthens Aenova’s capabilities in developing and manufacturing complex medications. US-based Cytovance Biologics has introduced in-house formulation development services, enhancing its role as a comprehensive partner for biologic drug developers. These services utilize quality-by-design principles to ensure speed, safety, and precision in current and future client programs.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available)  Ofichem acquires Avivia BV; Evonik, Samsung Biologics form strategic collaborations Europe-based CDMO Ofichem Group announced the acquisition of Avivia BV, a formulation development company in the Netherlands. This acquisition is part of Ofichem’s strategy to become a fully integrated provider of development solutions across both drug substance and drug product, with a focus on complex formulations. Ofichem has also acquired Meribel Pharma Solutions’ site in Uppsala (Sweden) to strengthen its support for biotech innovators and expand its presence in the Nordic region.  Simtra BioPharma Solutions has acquired a 65-acre property near its Bloomington, Indiana (US) facility, adding over 300,000 square feet of potential expansion space. With this site, Simtra now has the flexibility to rapidly expand in the US. German specialty chemicals company Evonik is partnering with German biotech Ethris to develop and commercialize a next-generation lipid nanoparticle (LNP) platform for delivering nucleic acid therapies. Evonik will assist in formulation using Ethris’ SNaP LNP technology. The LNP market alone is projected to grow to US$2.3 billion by 2032. Luxembourg-headquartered Fareva has partnered with Zhaoke Ophthalmology to expand its footprint in China’s pharma market. Zhaoke will act as Fareva’s go-to partner for customers seeking pharmaceutical manufacturing in China. Samsung Biologics has signed a 1.8 trillion won (US$ 1.3 billion) manufacturing agreement with an undisclosed US-based drugmaker. And UK-based eXmoor Pharma has partnered with Anthony Nolan to provide end-to-end services for cell therapy developers.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available)  Our view The global CDMO market, valued at around US$ 255 billion in 2025, is projected to grow to over US$ 465 billion by 2032. Significantly, about 60 percent of new drug approvals in the US and over 65 percent in Europe now involve CDMO support. The developments outlined above underscore the increasing role CDMOs are playing today in bringing about growth and innovation in the pharmaceutical industry.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4059

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-chemexpress-invest-in-adc-facilities-cohance-to-set-up-oligonucleotide-facility-in-india

    #PharmaFlow by PHARMACOMPASS
    16 Oct 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    AGC Pharma Chemicals to Attend CDMO Live Rotterdam
    AGC Pharma Chemicals to Attend CDMO Live Rotterdam

    29 Apr 2026

    // PRESS RELEASE

    https://www.agcpharmachemicals.com/en/news/agc-pharma-chemicals-to-attend-cdmo-live-rotterdam/

    PRESS RELEASE
    29 Apr 2026
    Share Share
    AGC Pharma to Attend Connection Day 2026 in Barcelona
    AGC Pharma to Attend Connection Day 2026 in Barcelona

    21 Apr 2026

    // PRESS RELEASE

    https://www.agcpharmachemicals.com/en/news/agc-pharma-chemicals-to-attend-connection-day-2026-in-barcelona/

    PRESS RELEASE
    21 Apr 2026
    Share Share
    AGC Pharma Chemicals will participate in CPHI Japan 2026
    AGC Pharma Chemicals will participate in CPHI Japan 2026

    08 Apr 2026

    // PRESS RELEASE

    https://www.agcpharmachemicals.com/es/noticias/agc-pharma-chemicals-participara-en-cphi-japan-2026/

    PRESS RELEASE
    08 Apr 2026
    Share Share
    AGC Pharma, recognized in 4 categories at CDMO Leadership Awards
    AGC Pharma, recognized in 4 categories at CDMO Leadership Awards

    31 Mar 2026

    // PRESS RELEASE

    https://www.agcpharmachemicals.com/es/noticias/agc-pharma-chemicals-distinguida-en-cuatro-categorias-en-los-premios-cdmo-leadership-awards-2026/

    PRESS RELEASE
    31 Mar 2026
    Share Share
    AGC Pharma Chemicals will attend DCAT Week 2026 in New York
    AGC Pharma Chemicals will attend DCAT Week 2026 in New York

    12 Mar 2026

    // PRESS RELEASE

    https://www.agcpharmachemicals.com/es/noticias/agc-pharma-chemicals-asistira-a-dcat-week-2026-en-nueva-york/

    PRESS RELEASE
    12 Mar 2026
    Share Share
    HPAPIs Are Transforming Pharmaceutical Manufacturing
    HPAPIs Are Transforming Pharmaceutical Manufacturing

    02 Feb 2026

    // PRESS RELEASE

    https://www.agcpharmachemicals.com/es/noticias/hpapis-que-estan-transformando-la-fabricacion-farmaceutica/

    PRESS RELEASE
    02 Feb 2026
    Share Share

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Services

    Discover the service capabilities from this company

    Analytical

    Discover their expertise for : Analytical

    API Manufacturing

    Discover their expertise for : API Manufacturing

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    KEY SERVICES

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Popup full-view
    Containment of High Potency API (HPAPI)
    full-view
    Lab-Scale And/Or Pilot Scale Experimentation
    full-view
    Small Molecule API Development Services
    full-view
    cGMP Production of APIs
    full-view
    Aseptic Micronization
    full-view
    Process Scale-Up & Optimization
    full-view

    Inspections and registrations

    Check the inspections & registration from this company
    Popup

    ABOUT THIS PAGE

    Contact AGC Pharma Chemicals Europe and get a quotation

    AGC Pharma Chemicals Europe is a supplier offers 7 products (APIs, Excipients or Intermediates).

    Find Dapiprazole Hydrochloride bulk offered by AGC Pharma Chemicals Europe

    Find Dipyridamole bulk offered by AGC Pharma Chemicals Europe

    Find Gliquidone bulk offered by AGC Pharma Chemicals Europe

    Find Mexiletine bulk offered by AGC Pharma Chemicals Europe

    Find Pimobendan bulk offered by AGC Pharma Chemicals Europe

    Find Pirenzepine bulk offered by AGC Pharma Chemicals Europe

    Find Telmisartan bulk offered by AGC Pharma Chemicals Europe

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search